The future cost of stroke in Ireland: an analysis of the potential impact of demographic change and implementation of evidence-based therapies.

BACKGROUND AND PURPOSE this paper examines the impact of demographic change from 2007 to 2021 on the total cost of stroke in Ireland and analyses potential impacts of expanded access to stroke unit care and thrombolytic therapy on stroke outcomes and costs. METHODS total costs of stroke are estimated for the projected number of stroke cases in 2021 in Ireland. Analysis also estimates the potential number of deaths or institutionalised cases averted among incident stroke cases in Ireland in 2007 at different rates of access to stroke unit care and thrombolytic therapy. Drawing on these results, total stroke costs in Ireland in 2007 are recalculated on the basis of the revised numbers of incident stroke patients estimated to survive stroke, and of the numbers estimated to reside at home rather than in a nursing home in the context of expanded access to stroke units or thrombolytic therapy. RESULTS future costs of stroke in Ireland are estimated to increase by 52-57% between 2007 and 2021 on the basis of demographic change. The projected increase in aggregate stroke costs for all incident cases in 1 year in Ireland due to the delivery of stroke unit care and thrombolytic therapy can be offset to some extent by reductions in nursing home and other post-acute costs.

[1]  A. Di Carlo.  Human and economic burden of stroke. , 2009, Age and ageing.

[2]  C. Mathers,et al.  Stroke incidence and prevalence in Europe: a review of available data , 2006, European journal of neurology.

[3]  A. Villringer,et al.  Medical resource use and costs of health care after acute stroke in Germany , 2005, European journal of neurology.

[4]  M. Giroud,et al.  Estimating the Cost-Effectiveness of Stroke Units in France Compared With Conventional Care , 2004, Stroke.

[5]  J. McNeil,et al.  Cost of Stroke in Australia From a Societal Perspective: Results From the North East Melbourne Stroke Incidence Study (NEMESIS) , 2001, Stroke.

[6]  Mark Nuijten,et al.  Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  D. O’Neill,et al.  Irish Heart Foundation National Audit of Stroke Care , 2008 .

[8]  C. Wolfe,et al.  Economic burden of stroke in England , 2005 .

[9]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[10]  Jeroen N. Struijs,et al.  International Comparison of Stroke Cost Studies , 2004, Stroke.

[11]  L. Wilhelmsen,et al.  Stroke Incidence and Mortality Rates 1987 to 2006 Related to Secular Trends of Cardiovascular Risk Factors in Gothenburg, Sweden , 2009, Stroke.

[12]  Mette Kjølby,et al.  Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke , 2007, Stroke.

[13]  M. Cowie,et al.  UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the General Practice Research Database , 2011, BMJ Open.

[14]  D. O’Neill,et al.  The cost of stroke and transient ischaemic attack in Ireland: a prevalence-based estimate. , 2012, Age and ageing.

[15]  J. Mar,et al.  Cost-Effectiveness Analysis of Thrombolytic Treatment for Stroke , 2005, Cerebrovascular Diseases.

[16]  P. Rothwell,et al.  Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature , 2009, Stroke.

[17]  Langhorne,et al.  Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke , 1997, BMJ.

[18]  J. McMurray,et al.  Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005 , 2009, Circulation. Cardiovascular quality and outcomes.

[19]  三澤吉雄.  In Canada … , 1980, Current History.

[20]  C. Mihalopoulos,et al.  Economic Evaluation of Australian Stroke Services: A Prospective, Multicenter Study Comparing Dedicated Stroke Units With Other Care Modalities , 2006, Stroke.

[21]  C. Wolfe,et al.  Cost of stroke in the United Kingdom. , 2008, Age and ageing.

[22]  Maarten Schrooten,et al.  Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale , 2009, Stroke.

[23]  C. Marra,et al.  Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. , 2001, PharmacoEconomics.

[24]  J M Wardlaw,et al.  Thrombolysis for acute ischaemic stroke. , 2003, The Cochrane database of systematic reviews.

[25]  Anna Czlonkowska,et al.  Underfunding of Stroke Research: A Europe-Wide Problem , 2004, Stroke.

[26]  D. Reid,et al.  Estimating the cost effectiveness of screening tests. , 1997, QJM : monthly journal of the Association of Physicians.

[27]  J. Struijs,et al.  Modeling the Future Burden of Stroke in the Netherlands: Impact of Aging, Smoking, and Hypertension , 2005, Stroke.

[28]  J. V. van Wijngaarden,et al.  Hospital Rates of Thrombolysis for Acute Ischemic Stroke: The Influence of Organizational Culture , 2009, Stroke.

[29]  Charles Normand,et al.  Projecting the Impact of Demographic Change on the Demand for and Delivery of Health Care in Ireland , 2009 .

[30]  J. Mar,et al.  Calculation of Prevalence with Markov Models: Budget Impact Analysis of Thrombolysis for Stroke , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  V. Feigin,et al.  Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review , 2009, The Lancet Neurology.

[32]  B. Demaerschalk,et al.  Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada , 2007, Stroke.